MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of our pivotal program in the coming months."